The Effects of a Combination of Medical Cannabis, Melatonin, and Oxygen-Ozone Therapy on Glioblastoma Multiforme: A Case Report
- PMID: 40729189
- PMCID: PMC12225241
- DOI: 10.3390/reports6020022
The Effects of a Combination of Medical Cannabis, Melatonin, and Oxygen-Ozone Therapy on Glioblastoma Multiforme: A Case Report
Abstract
Glioblastoma is the most aggressive malignant tumor overall and remains an incurable neoplasm with a median survival of 15 months. Since 2005, the gold standard treatment for glioblastoma has remained unchanged, and it is a common goal of the scientific community to work towards a better prognosis and improved survival for glioblastoma patients. Herein, we report a case of glioblastoma multiforme in a patient with a poor prognosis who, following partial removal of the neoplasm, refused conventional therapy consisting of a combination of radiotherapy and temozolomide-based chemotherapy due to personal serious side effects. The patient started an unconventional therapeutic path by alternating periods of oxygen-ozone therapy with concomitant administration of legal medical cannabis products (Bedrocan and Bedrolite) and melatonin. This approach resulted in a complete and durable remission of the disease and long survival. Indeed, the patient is still alive. The exceptional result obtained here encourages us to share and carefully investigate this unconventional treatment as a possible future direction in the management of glioblastoma.
Keywords: cannabinoids; chemotherapy; glioblastoma; melatonin; oxygen–ozone therapy; radiotherapy.
Conflict of interest statement
The authors declare no conflict of interest.
Figures





Similar articles
-
Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis.Cochrane Database Syst Rev. 2020 Mar 23;3(3):CD013261. doi: 10.1002/14651858.CD013261.pub2. Cochrane Database Syst Rev. 2020. PMID: 32202316 Free PMC article.
-
Effects and safety of TMZ plus RT combined with other drugs in the treatment of glioblastoma: a network meta-analysis.Future Oncol. 2025 Jul;21(17):2237-2249. doi: 10.1080/14796694.2025.2516408. Epub 2025 Jun 18. Future Oncol. 2025. PMID: 40528440
-
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450. Health Technol Assess. 2007. PMID: 17999840
-
Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.Cochrane Database Syst Rev. 2021 May 4;5(1):CD013579. doi: 10.1002/14651858.CD013579.pub2. Cochrane Database Syst Rev. 2021. PMID: 34559423 Free PMC article.
-
Congress of Neurological Surgeons systematic review and evidence-based guidelines for the role of chemotherapy in newly diagnosed WHO Grade II diffuse glioma in adults: update.J Neurooncol. 2025 Jan;171(2):279-298. doi: 10.1007/s11060-024-04861-6. Epub 2024 Nov 20. J Neurooncol. 2025. PMID: 39565459
References
-
- Louis D.N., Perry A., Wesseling P., Brat D.J., Cree I.A., Figarella-Branger D., Hawkins C., Ng H.K., Pfister S.M., Rei-fenberger G., et al. The 2021 WHO Classification of Tumors of the Central Nervous System: A summary. Neuro Oncol. 2021;23:1231–1251. doi: 10.1093/neuonc/noab106. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources